Anticancer agent 263
Anticancer agent 263 (compound 7) is a potent anticancer agent. Anticancer agent 263 binds to the G-quadruplex DNA (G4) sequence 22-mer Pu22, a mimic of c-Myc DNA. Anticancer agent 263 is a structure modulator, showcasing a significant enhancement in protein α-helix formation and the capability to form supramolecular network. Anticancer agent 263 shows no cytotoxicity[1].
Product Specifications
UNSPSC
12352211
Target
C-Myc
Related Pathways
Apoptosis
Field of Research
Cancer
Smiles
CC1(OC(C(C(NCCO)=O)=C1CC[C@@H](C(O)=O)N)=O)C
Molecular Formula
C13H20N2O6
Molecular Weight
300.31
References & Citations
[1]Hayarpi Simonyan, et al. Exploring the binding of c-Myc G-quadruplex and the structural impact of synthetic non-proteinogenic amino acids on serum albumins: implications for potential intrinsic c-Myc-associated anticancer activity and drug delivery systems. Molecular Therapy:Nucleic Acid. 2025.|[2]Hayarpi Simonyan, et al. Exploring the binding of c-Myc G-quadruplex and the structural impact of synthetic non-proteinogenic amino acids on serum albumins: implications for potential intrinsic c-Myc-associated anticancer activity and drug delivery systems. Molecular Therapy:Nucleic Acid. 2025.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
249359-ML750 100 µL
NME2 (Non-Metastatic Cells 2, Protein (NM23B) Expressed in, MGC111212, NDPK-B, NDPKB, NM23-H2, NM23B, puf) (MaxLight 750) discontinued
Sign In for Pricing
View Details 
GTR15262454 1 Vial
Lentiviral mouse Wdr41 shRNA (UAS) - Lentiviral mouse Wdr41 shRNA (UAS, iRFP) (25)
Sign In for Pricing
View Details